Employees Retirement System of Texas increased its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 31.8% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 344,000 shares of the biotechnology company’s stock after purchasing an additional 83,000 shares during the period. Employees Retirement System of Texas owned 0.18% of BioMarin Pharmaceutical worth $29,818,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of BMRN. ICA Group Wealth Management LLC acquired a new position in shares of BioMarin Pharmaceutical during the fourth quarter valued at approximately $31,000. MayTech Global Investments LLC acquired a new stake in BioMarin Pharmaceutical during the 4th quarter worth $36,000. Dark Forest Capital Management LP acquired a new stake in BioMarin Pharmaceutical during the 1st quarter worth $37,000. WealthPLAN Partners LLC purchased a new stake in shares of BioMarin Pharmaceutical during the first quarter worth $37,000. Finally, State of Wyoming acquired a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $41,000. 92.78% of the stock is owned by hedge funds and other institutional investors.
BioMarin Pharmaceutical Stock Performance
Shares of NASDAQ BMRN traded up $0.12 during midday trading on Tuesday, reaching $87.65. 215,739 shares of the company traded hands, compared to its average volume of 1,375,034. The stock has a 50-day moving average price of $85.66 and a 200 day moving average price of $88.88. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.54 and a quick ratio of 1.65. The company has a market cap of $16.51 billion, a price-to-earnings ratio of 113.68, a PEG ratio of 1.35 and a beta of 0.37. BioMarin Pharmaceutical Inc. has a 52 week low of $76.02 and a 52 week high of $117.77.
Wall Street Analyst Weigh In
BioMarin Pharmaceutical Profile
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
- Five stocks we like better than BioMarin Pharmaceutical
- How to Invest in Social Media
- Wynn Resorts has an ace up its sleeve
- Election Stocks: How Elections Affect the Stock Market
- Zoom Video Communications: A tech phoenix ready to rise
- How to Invest in Renewable Energy
- The only two airline stocks worth buying: One is a Goldman pick
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.